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Maria Duenas-Decamp,a Paul Peters,a Rongheng Lin,c Susan Zolla-Pazner,d Davide Corti,e Aaron Wallace,f Shixia Wang,f
Xiang-Peng Kong,g Shan Lu,f,h Paul R. Claphama
Program in Molecular Medicine and Department of Microbiology and Physiological Systems, University of Massachusetts Medical School, Worcester, Massachusetts, USAa;
Monogram Biosciences, South San Francisco, California, USAb; School of Public Health and Health Sciences, University of Massachusetts, Amherst, Massachusetts, USAc;
Department of Pathology, New York University Langone School of Medicine, New York, New York, USAd; Humabs Biomed SA, Bellinzona, Switzerlande; Department of
Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USAf; Department of Biochemistry, New York University School of Medicine, New York,
New York, USAg; China-U.S. Vaccine Research Center, Nanjing Medical University, Nanjing, Jiangsu, Chinah
HIV-1 R5 viruses vary extensively in their capacity to infect macrophages. R5 viruses that confer efficient infection of macro-
phages are able to exploit low levels of CD4 for infection and predominate in brain tissue, where macrophages are a major target
for infection. HIV-1 R5 founder viruses that are transmitted were reported to be non-macrophage-tropic. Here, we investigated
the sensitivities of macrophage-tropic and non-macrophage-tropic R5 envelopes to neutralizing antibodies. We observed strik-
ing differences in the sensitivities of Env pseudovirions to soluble CD4 (sCD4) and to neutralizing monoclonal antibodies
(MAbs) that target the CD4 binding site. Macrophage-tropic R5 Envs were sensitive to sCD4, while non-macrophage-tropic Envs
were significantly more resistant. In contrast, all Envs were sensitive to VRC01 regardless of tropism, while MAb b12 conferred
an intermediate neutralization pattern where all the macrophage-tropic and about half of the non-macrophage-tropic Envs were
sensitive. CD4, b12, and VRC01 share binding specificities on the outer domain of gp120. However, these antibodies differ in
their ability to induce conformational changes on the trimeric envelope and in specificity for residues on the V1V2 loop stem and
20-21 junction that are targets for CD4 in recruiting the bridging sheet. These distinct specificities of CD4, b12, and VRC01
likely explain the observed differences in Env sensitivity to inhibition by these reagents and provide an insight into the envelope
mechanisms that control macrophage tropism.We present a model where the efficiency of bridging-sheet recruitment by CD4 is
a major determinant of HIV-1 R5 envelope sensitivity to soluble CD4 andmacrophage tropism.
Human immunodeficiency virus type 1 (HIV-1) entry intocells involves interactions with CD4 and coreceptor CCR5 or
CXCR4 to trigger fusion of the virus and cell membranes. In vivo,
HIV-1 infection is limited mainly to cells expressing CD4 and an
appropriate coreceptor. These include T cells, macrophages, and
dendritic cells as well as their progenitors (1–3). In the past, HIV-1
R5 viruses that use CCR5were described asmacrophage-tropic or
M-tropic, reflecting a view that such viruses infectmacrophages in
addition to T cells (4–6). However, studies from our group and
others have shown that R5 viruses vary extensively in their capac-
ity to infect macrophages (7–14). This variation results mainly
from differences in the ability of HIV-1 to exploit low levels of
CD4 onmacrophages for infection (10, 12, 14, 15). Recent studies
reported that founder viruses transmitted either sexually (16, 17)
or via mother to child (18) were non-macrophage-tropic and that
they persist in immune tissue even in late disease (10, 12, 19).
Nevertheless, highly macrophage-tropic R5 variants are increas-
ingly detected in late disease (20–22) and are predominant in
brain tissue of subjects with HIV-associated neurocognitive dis-
orders (7, 10, 12, 14).
The HIV-1 envelope glycoprotein is a trimer comprising three
copies each of gp120 and transmembrane gp41. Many high-reso-
lution crystal structures of monomeric gp120 of HIV-1 have been
reported (23–28). However, all lack the V1V2 loops and carry
deletions andmutated glycosylation sites, and they frequently lack
the V3 loop. In addition, many represent the gp120 structure that
forms after gp120 has bound CD4 (29), with the bridging sheet
(usually recruited by CD4) fully assembled. The only unliganded,
high-resolution structure of gp120 that is distinct from the CD4-
bound forms was reported for simian immunodeficiency virus
(SIV) (30). This structure shows an unformed bridging sheet and
a more extended CD4 binding loop.
The different crystal structures of the gp120 monomers have
been augmented by less-resolved cryo-electron tomographic im-
ages of native Env trimers on virions (31–36). These structures
show that the V1V2 loops are positioned at the apex of the unli-
ganded trimer and proximal to the V3 loops. They also reveal how
the V1V2 loops move from the trimer apex when Env is activated
by CD4 (31, 33). The movement of V1V2 exposes V3 and releases
a determinant on the V1V2 stem for recruitment by CD4 and
bridging-sheet formation, thus enabling the formation and expo-
sure of the coreceptor binding site (26, 32). It remains less clear
how variations in the structure and function of the trimer control
a range of different Env properties, including R5macrophage tro-
pism and neutralization sensitivity.
Env determinants that control R5 macrophage tropism are
complex. Dunfee et al. identified an asparagine at residue 283
which is prevalent in macrophage-tropic Envs from brain and in
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individuals with neurological complications (7). Residue 283 is a
contact site for CD4, and an asparagine at that position confers a
higher affinity for CD4 and an increased ability to infect macro-
phages via low CD4 (7). We confirmed the role of N283 in mac-
rophage-tropic Env (12, 37). However, the identification of many
macrophage-tropic Envs that lack N283 (and non-macrophage-
tropic Envs with N283) indicates that other determinants play a
significant role (13, 19). We identified complex determinants that
included residues on the N-terminal flank of the CD4 binding
loop as well as changes in the glycan shield that may affect the
exposure of CD4 contact residues (37, 38). We also reported a
single residue in the V1 loop that modulated macrophage infec-
tivity (39) and identified determinants in the V3 loop that con-
tribute to macrophage tropism (37). Together these observations
implicate sites within or proximal to the CD4 binding site
(CD4bs) and at the apex of the trimer as determinants of R5mac-
rophage tropism.
Here, we investigated HIV-1 R5 Envs that differ in their capac-
ity to infect primary macrophages by measuring their sensitivities
to newly described potent neutralizing monoclonal antibodies
(MAbs) that target different Env sites, including the CD4bs (28,
40). In particular, we compared the potent CD4bs MAb VRC01
with b12 and solubleCD4 (sCD4).VRC01 andother highly potent
CD4bs MAbs with similar specificities were reported to mimic
binding of the host receptor CD4 (28, 41, 42). However, our data
show that VRC01 potently neutralized pseudoviruses via all of the
Envs tested, contrasting with sCD4, which was highly preferential
for macrophage-tropic Envs, and with b12, which neutralized all
macrophage-tropic but only some of the non-macrophage-tropic
Envs that carried the b12 epitope. These distinct specificities re-
flect different abilities of sCD4, b12, and VRC01 to induce con-
formational changes and to bind determinants on the bridging
sheet following attachment to the outer domain of gp120 on func-
tional trimers (26, 28, 43–45). The different neutralization profiles
and bridging-sheet specificities as well as distinct abilities to in-
duce conformational changes in the trimer have led us to conclude
that non-macrophage-tropic Envs are substantiallymore resistant
to CD4-induced conformational changes than highly macro-
phage-tropic R5 variants. The ability of CD4 to recruit the bridg-
ing sheet is therefore a major determinant of HIV-1 R5 macro-
phage tropism.
MATERIALS AND METHODS
HIV-1 envelope glycoproteins.We selected 48HIV-1 R5 Envs, including
many that were clearly macrophage-tropic or non-macrophage-tropic
(Table 1). We included Envs that had been well characterized in our pre-
vious studies for tropism and other properties (10–12, 19, 37). Where
possible, we included groups of Envs that had been amplified from single
individuals and that included both macrophage-tropic and non-macro-
phage-tropic Envs.Mainly, we used a panel of Envs that we had previously
studied (11) and includedmore recently amplified and characterized Envs
(19).
PreparationandtitrationofEnvpseudovirions.env revpSVIIIenvor
pcDNA3.1D/V5-His-TOPOwere cotransfected into 293T cells with env
pNL43. Env pseudovirions were harvested after 48 h, clarified by low-
speed centrifugation, and frozen as aliquots at 152°C. Env pseudovi-
TABLE 1 HIV-1 envelope clones
Patient
Macrophage-tropic Envs Non-macrophage-tropic Envs
Envelope Origin Envelope Origin
NA20 B59 Brain LN3 Lymph node
B76 Brain LN8 Lymph node
B501 Brain LN10 Lymph node
23-14-2 Lymph node LN14 Lymph node
LN16 Lymph node
NA420 B13 Brain LN40 Lymph node
B33 Brain LN85 Lymph node
B42 Brain
NA118 B12 Brain
LN27 Lymph node
LN33 Lymph node
NA176 B93 Brain
NA353 B27 Brain
7766 FL1 (FL19-54-50) Brain SP1 (SP13-33-41) Spleen
6568 FL1 (FL11-1-249) Brain SP1 (SP6-11-9) Spleen
10017 FL1 (FL9-1-2) Brain SP2 (SP10-9-65) Spleen
SP3 (SP9-8-57) Spleen
CA110 OC1 (OC58-11-9) Brain SP1 (SP52-13-34) Spleen
P1114 C98-15 Plasma C95-65 Plasma
C98-18 Plasma C96-26 Plasma
C98-27 Plasma
C98-28 Plasma
C98-67 Plasma
P43 380.1 Semen 378.2 Blood
380.4 Semen
P3 164-1.4 Blood
180-6.4 Blood
196-10.1 Semen
197-9.3 Semen
199-8.5 Semen
P31 350.1 Blood
351.6 Blood
308.2 Semen
JR JR-FL Brain JR-CSF Cerebrospinal
fluid
FIG 1 R5 macrophage-tropic Env pseudovirions are more sensitive to neu-
tralization by sCD4 but not VRC01.Mann-Whitney analyses comparingmac-
rophage-tropic and non-macrophage-tropic Env pseudovirions for sensitiv-
ity to sCD4 andCD4bsMAbs are shown. Only for sCD4was there a significant
difference in sensitivity between macrophage-tropic and non-macrophage-
tropic Env pseudovirions. Nonparametric, two-tailed tests were carried out
on IC50s for sCD4 and each CD4bs MAb. See also Table 2.
O’Connell et al.
188 jvi.asm.org Journal of Virology
 o
n
 August 9, 2013 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
rions were titrated on HeLa TZM-BL cells, which carry -galactosidase
and luciferase reporter genes controlled by HIV long terminal repeat
(LTR) promoters (46). Infected cells were visualized at 48 h after infection
as focus-forming units (FFU) following staining for-galactosidase activ-
ity. Since Env pseudovirions are capable of only a single round of repli-
cation, individual cells or small groups of divided cells were counted as
foci.
Neutralization and inhibition assays. Neutralization and inhibition
assays were performed as described previously using HeLa TZM-BL cells
and a luminescence readout (12).
Production of monomeric gp120. Monomeric gp120 was produced
in 293T cells. Briefly, pJW4303 carrying gp120 sequences was transfected
into 293T cells using calcium phosphate. Supernatant was harvested after
48 h and clarified by low-speed centrifugation, protease inhibitor added,
and aliquots frozen at80°C.
Determination of ligand binding to monomeric gp120 by ELISA.
The amount of gp120 in 293T supernatants was estimated by titration
using a capture enzyme-linked immunosorbent assay (ELISA) and by
comparison to a standard concentration of IIIB gp120 (47). To estimate
binding of CD4bs MAbs to gp120, serial 2-fold dilutions of each MAb
were added to captured gp120. A dilution of gp120 that saturated the
capture antibody was used throughout.
Statistical analyses. Fifty percent inhibitory concentrations (IC50s)
for the different MAbs, sCD4, T20, and maraviroc were estimated by
GraphPad Prism 5 for Mac OS X and confirmed using a robust semipa-
rametric regression model (48) implemented by R package drc (49).
When no inhibitionwas observed, when inhibition failed to reach 50%, or
when the model-fitting algorithms either did not converge or reported an
extrapolating estimate out of the experimental ranges with a very wide
confidence interval, we report the lower dose boundary (e.g.,50g/ml)
or winsorized IC50 estimates obtained manually from Excel plotted
graphs. Two-tailed, nonparametric Mann-Whitney tests were used to
evaluate whether statistically significant differences existed between dis-
tributions of IC50s for the different ligands between macrophage-tropic
and non-macrophage-tropic envelopes. Correlations were tested using
nonparametric, two-tailed Spearman analyses.
RESULTS
Sensitivities ofmacrophage-tropic andnon-macrophage-tropic
R5 Env pseudovirions to neutralization by broadly active CD4
binding site monoclonal antibodies. Highly macrophage-tropic
R5 Envs are consistently detected in brain tissues of subjects with
HIV-associated neurological issues (7, 9, 10, 12–14). The brain is
TABLE 2 Sensitivities of HIV-1 Env pseudovirions to neutralization by sCD4 and CD4bs
MAbs
a IC50s: red,1.0 g/ml; yellow,1 g/ml,10 g/ml; green,10 g/ml,50 g/ml. NT, not tested.
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protected by the blood-brain barrier, which limits the amount of
immunoglobulin present (50–52). HIV variants replicating in the
brain are thus not exposed to the high levels of neutralizing anti-
bodies that bombard their counterparts in immune tissue. We
expected thatHIV variants in the brainmight have evolved amore
open structure so that CD4 contact residues are more efficiently
exposed to enhance Env-CD4 interactions. Such Envs would then
be able to confer infection of brain macrophages that express
lower levels of CD4 than CD4 T cells (53–55).
In an earlier study, we reported that R5macrophage tropism
correlated with sensitivity to sCD4 inhibition (11). Thus, pseu-
dovirions carrying macrophage-tropic Envs were generally
sensitive and non-macrophage-tropic Envs more resistant. Ini-
tially, we concluded that this observation supported a more
exposed CD4bs on macrophage-tropic R5 Envs than on non-
macrophage-tropic Envs. However, when we tested Env pseu-
dovirions for their sensitivities to CD4bs MAbs b12 and b6, we
did not detect a clear correlation with macrophage tropism
(11). Here, we investigated the sensitivities of an extended
panel of Env pseudovirions (Table 1) to newly described
CD4bs MAbs, including VRC01 and VRC03 (28, 43) and HJ16
(56) and compared with b12 and sCD4 (Fig. 1 and Table 2).
Our results show that the neutralization patterns for each of the
different CD4bs MAbs varied considerably. They confirm a
highly significant correlation between macrophage tropism
and sensitivity to sCD4 but not b12. In addition, there was no
correlation between macrophage infectivity and sensitivity to
VRC01, VRC03, or HJ16. Moreover, VRC01 neutralized all
Env pseudovirions tested regardless of macrophage tropism
or tissue origin, while VRC03 inhibited about 70% of the pseu-
dovirions, without a significant correlation with tropism.
Env resistance to the broadly active CD4bsMAbs could be due
to amino acid variation within the epitope that abrogates MAb
recognition. Alternatively, it is possible that the target epitope is
sterically blocked or in a different conformation in the context of
the trimeric envelope spike even though it is present on themono-
mer. We investigated whether the b12 epitope could be detected
on monomeric gp120s derived from resistant and sensitive Envs
using ELISAs. Our results show that the three macrophage-tropic
Envs (NA176 B93, 7766 FL1, and CA110 OC1), which resisted
b12, reacted poorly in ELISAs, explaining their resistance (Fig.
FIG 2 Presence and exposure of b12 and 447-52D epitopes on neutraliza-
tion-sensitive and -resistant Envs. Results of ELISAs estimating CD4bs
MAb b12 and V3 loopMAb 447-52D binding to monomeric gp120 derived
from resistant and sensitive Envs are shown. (A) Monomeric gp120 from
b12-resistant macrophage-tropic Envs (red symbols) (B93, 7766 FL1, and
CA110 OC1) does not efficiently bind b12. In contrast, gp120 from b12-
resistant non-macrophage-tropic Envs (yellow symbols) (C98-27, LN8,
and LN40) bind as strongly as sensitive macrophage-tropic Envs (green
symbols), indicating that the b12 epitope is present on the monomer but
protected on the functional trimer. These data also indicate that all mac-
rophage-tropic R5 Envs that carry the b12 epitope are sensitive to b12
(Table 2). (B) The 447-52D epitope was detected on monomeric gp120
from 447-52D neutralization-sensitive macrophage-tropic C98-15 and
B33 as well as on gp120 from neutralization-resistant C98-27 and LN40
Envs derived from subjects P1114 and NA420, respectively. These data
indicate that the 447-52D epitope is present on resistant envelopes C98-27
and LN40 but is hidden or in a different conformation on the trimer.
Similarly, gp120s from NA20 LN8, NA176 B93, JR-FL, and JR-CSF each
bound to 447-52D efficiently, even though Env pseudovirions were resis-
tant to neutralization. The 447-52D epitopes of these Envs are therefore
not presented on the trimer. In contrast, gp120s from NA176 B93, 7766
FL1, and NA20 B59 (symbols with thick borders) bound 447-52D ineffi-
ciently, which explained their resistance to neutralization by this MAb.
These last three Envs lack the GPXR motif on the V3 crown that is targeted
by 447-52D (Table 4).
FIG 3 Macrophage-tropic R5 Env pseudovirions are not significantly more
sensitive to neutralizing antibodies in HIV-1 sera. Mann-Whitney analyses
comparing macrophage-tropic and non-macrophage-tropic Env pseudovi-
rions for sensitivity toHIV-1human sera are shown. Therewas no significant
difference in the sensitivities of macrophage-tropic and non-macrophage-
tropic Env pseudovirions to neutralization by 5 different HIV-1 human
sera. See also Table 3.
O’Connell et al.
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2A). In contrast, monomeric gp120s from non-macrophage-
tropic LN8 and LN40 bound b12 strongly, indicating that the
epitope was present but either sterically protected or conformed
differently on the trimer (Fig. 2A).
These data show that macrophage-tropic Envs were all sensi-
tive to sCD4, VRC01, and b12 (if the b12 epitope was present). In
contrast, the non-macrophage-tropic Envs were much more re-
sistant to sCD4, partially sensitive to b12, and universally sensitive
to VRC01 (Fig. 1; Table 2). Since VRC01 shares overlapping bind-
ing sites with CD4 and b12 on gp120, these data are striking.
Sensitivities of macrophage-tropic and non-macrophage-
tropic Envs to heterologous neutralizing antibodies in HIV-1
sera. If macrophage-tropic envelope trimers carry a more open
structure, then they would be expected to be generally more sen-
sitive to neutralizing antibodies in HIV-1-positive (HIV-1) sera.
To investigate this, we selected 5 HIV-1 sera that conferred
strong heterologous neutralizing activity. The results shown in
Fig. 3 and Table 3 reveal that these sera neutralized both mac-
rophage-tropic and non-macrophage-tropic Env pseudovirions
without significant differences. The neutralization specificities of
theseHIV-1 sera are not known.However, it is worth noting that
therewere highly significant correlations of IC50s for sera 8735-92,
30194-64, and Z01679 with those for VRC01 but not for sCD4 (P
values of 0.0002. 0.0014, and 0.007, respectively, for correlations
with VRC01 [Spearman analyses]).
Sensitivity of Env pseudovirions to 447-52D, PG9, and
PG16 indicates that some macrophage-tropic R5 Envs have al-
terations in the V1, V2, and V3 loops at the apex of the trimer.
Several studies have identified residues within or proximal to the
CD4bs as determinants of macrophage tropism (7, 12, 37). How-
ever, we also previously identified a conserved residue in the V1
loop that modulated macrophage infectivity for about 25% of
Envs tested (39) and showed that residues within V3 contributed
to macrophage tropism (37). In the unliganded Env, the V1V2
TABLE 3 Sensitivities of HIV-1 Env pseudovirions to neutralization by heterologous
neutralizing antibodies present in HIV-1 sera
a IC50s: red,1,000 reciprocal serum dilution; yellow,100 reciprocal serum dilution,1,000 reciprocal
serum dilution; green,10 reciprocal serum dilution,100 reciprocal serum dilution.
HIV-1 R5 Macrophage Tropism and Bridging-Sheet Recruitment
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loops are located at the trimer apex close to the V3 loop. During
entry, the V1V2 loops are repositioned following CD4 binding to
expose V3 and allow bridging-sheet determinants on the V1V2
stem to be recruited. The identification ofV1 andV3 loop residues
that affect infection ofmacrophages via lowCD4 is consistentwith
alterations at the apex of the trimer that facilitate V1V2movement
and bridging-sheet formation following CD4 binding. To investi-
gate whether structural alterations at the trimer apex could be
detected, we tested the sensitivities of macrophage-tropic and
non-macrophage-tropic Envs to neutralizing antibodies that bind
the V3 loop (447-52D binds the V3 loop crown [57]) or that rec-
ognize quaternary sites on V2 and V3 loops (PG9 and PG16 [58]).
Table 4 shows that several macrophage-tropic Envs derived
from two subjects (P1114 and NA420) were sensitive to V3 loop
MAb 447-52D, while all non-macrophage-tropic Envs (including
related Envs from the same individuals) were resistant. Sensitive
Envs included C98-15 (which we previously reported [39]) and
three Envs from patient NA420 (B33, B13, and B42).
We next used ELISAs to assess whether resistant macrophage-
tropic or non-macrophage-tropic Envs carried the 447-52D
epitope on monomeric gp120 to establish the extent that the 447-
52D epitope was protected from exposure on the trimer. Several
gp120s derived from macrophage-tropic R5 Envs that were resis-
tant to 447-52D failed to bind efficiently (e.g., CA110 OC1, 7766
TABLE 4 Sensitivities of HIV-1 Env pseudovirions to neutralization by the V3 loop-
specific MAb 447-52D and to PG9 and PG16, which bind to a quaternary epitope that
contains determinants in the V2 and V3 loops
a 447-25D recognizes the GPGR motif on the crown of the V3 loop (57).
b IC50s for 447-52D: yellow,10 g/ml; green,10 g/ml,50 g/ml.
c The PNG at asparagine 160 is a dominant target for PG9 and PG16 (58).
d IC50s for PG9 and PG16: red,0.1 g/ml; tan,0.1 g/ml,1.0 g/ml; yellow,1.0 g/ml,10 g/ml.
O’Connell et al.
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FL1, and NA20 B59). However, for NA176 B93 and JR-FL, there
was strong binding, indicating that the epitope was present but
either protected within the trimer or in a conformation not rec-
ognized (Fig. 2B). Similarly, several non-macrophage-tropic
gp120s tested (NA20 LN8, NA420 LN40, and P1114 C98-27)
showed strong binding to 447-52D, confirming that the epitope
was present on the monomer but not presented on the trimer.
These binding data are also consistent with the presence or ab-
sence of the V3 loop sequence (GPXR) that represents the pre-
dominant target sequence for 447-52D (57) (Table 4).
Together, these data indicate that some of the macrophage-
tropic Envs carried an exposed 447-52D epitope, consistent with
increased exposure of the V3 loop crown. Nevertheless, for other
highly macrophage-tropic Envs (e.g., NA176 B93) the 447-52D
epitope was protected on the trimer even though it was efficiently
recognized on the monomer. Exposure of the V3 loop crown is
therefore apparent for some of the macrophage-tropic Envs but is
not universal.
We also tested MAbs PG9 and PG16, which predominantly
target a glycan (N160) at the N terminus of V2 but are strongly
affected by determinants in the V3 loop (58). Our rationale was
that these MAbs might also detect differences in the arrangement
of V1V2 and V3 at the trimer apex. Our data show that mac-
rophage-tropic and non-macrophage-tropic Envs from several
individuals showed divergent sensitivities to PG9 or PG16 (Table
4). These sets included JR-CSF and JR-FL as well as Envs from
subjects NA20 and 10017, where non-macrophage-tropic Envs
were sensitive to both MAbs, while macrophage-tropic envelopes
were resistant. Curiously, Envs from subject 43 showed reversed
sensitivity and resistance to PG9 and PG16. Nevertheless, for Envs
that carried the N160 glycan (which is critical for PG9 and PG16
binding [58]), a significant difference in sensitivity between mac-
rophage-tropic and non-macrophage-tropic Envs was detected
for PG9 (P 0.002) but not quite for PG16 (P 0.05) (Fig. 4). In
summary, our data with 447-52D, PG9, and PG16 have identified
sets of Envs from 6 of 11 individuals where there is evidence con-
sistent with a different arrangement of V1V2 and V3 loops at the
trimer apex for macrophage-tropic and non-macrophage-tropic
Envs.
Limited changes in the sensitivity of macrophage-tropic R5
Envpseudovirions toMAbs and reagents that target other Env
sites anddownstreamevents in fusion.Wenext investigated the
panel of Envs for their sensitivities to MAbs or reagents that
target other Env sites or entry events subsequent to Env-CD4
binding. This approach was aimed at establishing whether Env
changes that led to increased or decreased macrophage tropism
were localized within or proximal to the CD4bs and at sites on
the trimer apex or, alternatively, conferred more extensive ef-
fects on Env structure that would affect other functions, in-
cluding coreceptor interactions and gp41 conformational
changes that result in fusion. Non-macrophage-tropic Envs
were significantly more sensitive to 2G12 than macrophage-
tropic Envs (P 0.006), confirming our previous observations
on a smaller panel of Envs (11). 2G12 binds to a glycan complex
on the outer domain of gp120. The decreased sensitivity to
2G12 for macrophage-tropic Envs is likely associated with the
loss of a critical glycan or a change in the orientation of one or
FIG 4 Macrophage-tropic R5 Env pseudovirions are significantly more re-
sistant to PG9 neutralization but not to PG16.Mann-Whitney analyses com-
paring macrophage-tropic and non-macrophage-tropic Env pseudovirions
for sensitivity to MAbs PG9 and PG16 (which recognize a quaternary epitope
comprising determinants in V2 and V3), are shown.
FIG 5 Macrophage-tropic R5 Env pseudovirions do not significantly differ
from non-macrophage-tropic Envs in sensitivity to maraviroc, T20, 2F5, and
4E10. However, macrophage-tropic R5 Envs are significantlymore resistant to
neutralization by the glycan-specific MAb 2G12. Mann-Whitney analyses
comparing macrophage-tropic and non-macrophage-tropic Env pseudovi-
rions for sensitivity to the CCR5 antagonist maraviroc, the 6-helix bundle
inhibitor T20, gp41 MAbs 4E10 and 2F5, and the gp120 glycan-specific MAb
2G12 are shown.
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more glycans, as we previously reported (38). Such changes
most likely influence exposure of CD4 contact residues on the
outer domain of gp120, although effects on coreceptor inter-
actions are also possible. Figure 5 and Table 5 show that there
were no significant differences between macrophage-tropic
and non-macrophage-tropic Envs in sensitivity to maraviroc
or to each of the gp41 reagents, including MAbs 2F5 and 4E10,
or to the fusion inhibitor, T20. Together, these data indicate
that major or “global” structural or functional alterations be-
tween trimers of macrophage-tropic and non-macrophage-
tropic Envs were not apparent and emphasize that the differ-
ences described above are localized to sites within or proximal
to CD4 contact residues and to the trimer apex.
DISCUSSION
We report striking differences in the ability of sCD4 and different
CD4bs ligands to neutralize macrophage-tropic and non-mac-
rophage-tropic R5 Env pseudovirions. While sCD4mainly neu-
tralized macrophage-tropic Envs, VRC01 conferred efficient neu-
tralization of all Env pseudovirions regardless of tropism. The
CD4bs MAb b12 conferred an intermediate pattern where all
macrophage-tropic Envs that carried the b12 epitope were neu-
TABLE 5 Sensitivities of HIV-1 Env pseudovirions to neutralization or inhibition by
reagents that bind envelope sites distal from the CD4bs and/or block entry events
downstream from CD4 binding
a IC50s for maraviroc: red,1 ng/ml; yellow,10 ng/ml,1 ng/ml.
b IC50s for MAbs 2G12, 4E10, and 2F5: red,1 g/ml; yellow,10 g/ml,1 g/ml; green,50 g/ml,10
ng/ml.
c IC50s for T20: red,0.1 g/ml; yellow,1 g/ml,0.1 g/ml; green,10 g/ml,1 g/ml.
O’Connell et al.
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tralized, while some but not all of the non-macrophage-tropic
Envs were sensitive. The new and potent CD4bs MAbs, e.g.,
VRC01, have been described as “highly active agonistic antibodies
against the CD4 binding site (HAADs) that mimic binding of the
host receptor CD4” (41). The binding sites for VRC01, b12, and
sCD4 overlap on the outer domain of gp120 (26, 41, 43, 45). How-
ever, these reagents have different requirements for binding the
bridging sheet and vary in their capacities to induce conforma-
tional changes in the trimer (43). CD4 recruits determinants on
the stem of the V1V2 loops and at the junction of the 20-21
strands to assemble the bridging sheet present on the gp120/sCD4
structure (26). However, the V1V2 stem determinant that binds
CD4 is not critical for binding either of these MAbs (28, 45).
Nevertheless, b12 does induce conformational changes in the
trimer, although less extensively than CD4 (32). In contrast,
VRC01, like other recently described potent CD4bs MAbs
(PGV04, 3BNC117, andNIH45-46) (42), does not induce confor-
mational changes on the trimer (43, 59). Finally, while mutation
of bridging-sheet determinants was reported to confer profound
effects on sCD4 and, to a lesser extent, b12 neutralization, they
barely affect VRC01 (43). These distinct specificities of CD4, b12,
and VRC01 for the bridging sheet along with their different abil-
ities to neutralize via macrophage-tropic and non-macrophage-
tropic Envs have led us to propose that R5 macrophage tropism is
determined by the ability of CD4 to recruit contact residues on the
V1V2 stem and 20-21 junction to assemble the bridging sheet
(Fig. 6).
The ability of CD4 to recruit the bridging sheet may be influ-
enced by changes within or proximal to CD4 contact residues,
which directly affect the affinity of the Env for CD4. An increased
Env-CD4 affinity potentially leads to a slower “off rate” (as re-
ported for gp120 carrying N283 [7]), thus increasing the time
frame for the V1V2 stem to be bound by CD4. Alternatively, an
increased affinity for CD4 may enhance the induction of confor-
mational changes that move V1V2 at the apex of the trimer, again
increasing the likelihood that the V1V2 stem will be exposed and
bound by CD4. An additional mechanism involves the ease with
which conformational changes are elicited by CD4 binding, i.e.,
movement of the V1V2 loops away from V3 at the trimer apex
(31). Our experiments with 447-52D, PG9, and PG16 have sug-
gested that (at least for some Envs) the V3 loop may be more
exposed or that the arrangement of V1V2 and V3 loops is altered
at the trimer apex. For C98-15, a conserved V1 residue controls
macrophage tropism aswell as sCD4 and 447-52D sensitivity (39),
unequivocally associating a single V1 residue at the trimer apex
with V3 loop exposure, CD4 binding, and macrophage tropism.
The data presented here incorporating VRC01 sensitivity now im-
plicate accessibility of CD4 contact residues on the bridging-sheet
segments as the major factor in determining low CD4 use and
macrophage tropism.
Our data show that the Env determinants that conferHIV-1R5
macrophage tropism are focused on the Env’s interaction with
CD4 and the immediate ensuing conformational changes and do
not reflect major changes in envelope structure. This is evident
from the lack of correlations between macrophage tropism and
sensitivity to other neutralizing MAbs or inhibitors that target
gp120-coreceptor interactions or gp41 conformational changes as
well as by the consistent insensitivity of all Envs to the CD4i MAb
17b (data not shown) The absence of significant variation in sen-
sitivities to these reagents further emphasize the marked differ-
ence in sensitivity to trimer apex reagents 447-52D, PG9, and
PG16 discussed above. Perhapsmost surprisingly, we were unable
to detect differences in sensitivity to heterologous neutralizing
antibodies inHIV-1 human sera. Sincemost of themacrophage-
tropic Envs used here were derived from the immune-privileged
environment of brain tissue (50–52), we had expected them to
have evolved a more open structure that would expose antibody
epitopes and confer increased sensitivity to neutralizing antibod-
FIG 6 Model showing how Env substitutions affect macrophage tropism of R5 Envs. Substitutions in gp120 residues that increase macrophage tropism occur
in residues directly contacting CD4 or that affect their exposure. These substitutions confer an increased affinity for CD4 and may slow the “off rate,” making it
more likely that theV1V2 stemon the inner domainwill be recruited. Alternatively, a higher affinity for gp120maymore efficiently induce gp120 conformational
changes so that the V1V2 stem is exposed for CD4 binding. Finally, substitutions in residues at sites on the trimer apex may facilitate conformational changes
induced by CD4, which move the V1V2 loops to expose both the V1V2 stem and the V3 loop for binding to CCR5.
HIV-1 R5 Macrophage Tropism and Bridging-Sheet Recruitment
January 2013 Volume 87 Number 1 jvi.asm.org 195
 o
n
 August 9, 2013 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
ies. However, while Envs may evolve enhanced exposure of CD4
contact residues and subtle exposure of V3 residues at the trimer
apex, they have not incurred more extensive alterations that
would confer a more global neutralization sensitivity.
Previously, we had hypothesized that a more open structure of
macrophage-tropic R5 Envs evolving in the brain would effi-
ciently expose the CD4bs along with conserved neutralization
epitopes and have relevance for vaccine development. Our data do
not support a wide-open structure for such Envs. However, the
identification of residues proximal to CD4 contact sites on the
outer domain of gp120 that modulate macrophage tropism (37)
and evidence for alterations in the glycan shield (as indicated by
the increased resistance of macrophage-tropic Envs to 2G12) may
indicate increased exposure of sites on the gp120 outer domain
that are the initial contacts for CD4. Such Envs may more readily
elicit antibodies targeting CD4 contact sites on the outer domain
and have application for vaccine development.
In summary, our data point to a model where R5 macrophage
tropism depends on the ability of CD4 to recruit bridging-sheet
determinants on the V1V2 stem and the 20-21 junction. Differ-
ent mechanisms can be envisaged to achieve this, which involve
changes in (i) CD4 contact residues that directly affect affinity for
CD4, (ii) proximal or distal residues that affect exposure of CD4
contact residues, including the loss or change in the orientation of
glycans that protect CD4 contact residues, and (iii) residues at the
trimer apex that facilitate conformational changes induced by
CD4. HIV-1 Envs in the brain may evolve to be highly macro-
phage-tropic via all three mechanisms. Thus, their increased ca-
pacity to bind and respond to CD4will enable the efficient forma-
tion and exposure of the bridging sheet and coreceptor binding
site in the presence of low levels of CD4 on the surfaces of macro-
phages.
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